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Chronic obstructive pulmonary disease (COPD)
can be accompanied by compensatory secondary
erythrocytosis. However, the exact prevalence of
secondary erythrocytosis in COPD is unknown.
Although diagnostic criteria for polycythemia vera
versus secondary erythrocytosis are mutually
exclusive, we describe here the coexistence of
polycythemia vera and COPD in the same patient. 
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Polycythemia is a rather common finding inclinical practice. The distinction betweenpolycythemia vera (PV) and secondary poly-
cythemias (SP) is crucial both for prognosis and
treatment. Flowcharts have been developed and
standardized, which enables the clinician to distin-
guish between these two entities.1
Chronic obstructive pulmonary disease (COPD)
can be accompanied by compensatory SP.2
However, the exact prevalence of SP in COPD is
unknown. Although diagnostic criteria for PV ver-
sus SP are mutually exclusive, we describe here the
coexistence of PV and COPD in the same patient. 
Case Report
A 67-year-old man (G.B.) was hospitalized
because of fever, productive cough, and worsening
dyspnea. The first evaluation showed an agitated,
obese man in respiratory distress with fever (38°C),
orthopnea, tachypnea (25 breaths/min) and
marked cyanosis. There were mild ankle edema,
jugular venous distension and digital clubbing.
Physical examination of the thorax showed signs of
chronic emphysema, mild wheezing, a left pleural
friction rub and bibasilar inspiratory rales. There
were also splenomegaly and mild hepatomegaly.
The remaining physical examination was unremark-
able. Arterial blood gases (evaluated while the
patient was breathing room air) were as follows:
pCO2: 63 mmHg; pO2: 37 mmHg; sO2: 65%; pH:
7.37. Laboratory tests showed erythrocytosis (RBC:
6.2131012/L; Hb: 18.3 g/dL; Hct: 0.61) and mild
thrombocytosis (4583109/L). Normal ranges for
men with the electronic counter Coulter S-Plus IV
are the following: RBC = 4.52-5.931012/L; Hb = 14-
17.5 g/dL; Hct = 0.42-0.50; plt = 130-4003109/L.
The red cell indices, white cell number, differential
count and peripheral blood cell morphology were
normal. Serum LDH was 590 mU/mL (normal
range = 200-460 mU/mL). The other routine labo-
ratory tests were within the normal range. Chest X-
ray showed bilateral fibrothorax, pulmonary emphy-
sema, congestion of the pulmonary vasculature and
a right-sided pleural effusion (Figure 1a). In a lat-
ero-lateral view (not shown) a right retrocardiac
inflammatory infiltrate was present. The patient was
a retired policeman. He had smoked about 40 ciga-
rettes a day since the age of 25, having quitted at
the age of 61 for respiratory problems. He also
admitted habitual abundant food and alcohol
intake. At the age of 21, he was treated with thera-
peutic pneumothorax for tuberculosis. At the age of
40, chronic bronchitis was diagnosed. In the follow-
ing years, he was found to be polycythemic (Hb: 18-
19 g/dL) and regularly donated blood till the age of
56. In the last four years the patient experienced
worsening dyspnea and noticed swollen feet.
At a first glance, this clinical presentation does not pose
particular problems. In a patient with COPD, fibrothorax
and myocardial insufficency, a lower airway infection wors-
ened a pre-existing respiratory failure. The erythrocytosis
and the thrombocytosis are easily attributable to the
chronic respiratory insufficency and to the acute infection,
respectively. Excessive alcohol intake and cardiac failure
could account for the hepato-splenomegaly.
In the hospital, the patient was treated with oxy-
gen by mask, i.v. furosemide, theophylline, cef-
tazidime and underwent 5 phlebotomies for a total
of 1,500 mL of blood. After a few days, the fever
had disappeared and the signs of cardiac and res-
piratory insufficency were improved. Arterial blood
gases (in room air) were as follows: pCO2: 45
mmHg; pO2: 61 mmHg; sO2: 86%; pH: 7.40.
Laboratory tests showed a reduction of plasma Hb
184
to 16.1 g/dL and Hct to 0.55, increased plasma
LDH (1040 mU/mL) and were otherwise un-
changed. The platelet count was only slightly
increased (4713109/L).
Spirometric tests yielded the following results: 
– FVC: 3.89 L (94% of predicted value); 
– FEV1/VC: 75% (62% of predicted value);
– RV: 3.17 L (123% of predicted value);
– DLCO: 4.3 mmol/KPa.min (46% of predicted
value).
These data demonstrated a conspicuous impairment of
both ventilation (obstructive type) and alveolar gas diffu-
sion.
An ultrasound scan of the upper abdomen
showed that the liver was within the normal limits
for size and echostructure, and confirmed the pres-
ence of splenomegaly (vertical diameter 230 mm).
No signs of portal hypertension were detected.
Despite the clear evidence of COPD with SP, we suspect-
ed the patient might be affected by a chronic myeloprolifera-
tive disorder. Clues for this suspicion were the presence of
splenomegaly, the increasing levels of serum LDH, the per-
sistence of thrombocytosis, and the lower than expected
decrease of Hb and Hct after repeated phlebotomies. It
should be noted that frequently splenomegaly, due to a
sequestering effect, lowers the blood cell count. We were
conscious that these facts were a fragile support to the diag-
nosis of a myeloproliferative syndrome, being realistically
attributable to the recent acute infection, chronic alcoholic
liver disease and cigarette smoking. 
The patient underwent the following investiga-
tions: 
– bone marrow aspirate: dry tap after 4 attempts.
– bone marrow biopsy: the bone marrow was
hypercellular, with a cell/fat ratio of 5:1. Myelo-
erythroid ratio was 3:1. The erythroid lineage was
slightly increased, with normal maturation. The
most striking feature was a marked increase of
the megakaryocytes, often clustered in groups of
10-15 elements. Among these, a great variability
of shapes and sizes was present, together with a
significant amount of micromegakaryocytes
(Figure 1b). A slight increase in the reticulin net-
work was observed with specific stain (Figure 2a);
– cytogenetics on peripheral blood leukocytes: no
mitoses were observable;
– leukocyte alkaline phosphatase (LAP) score: 42
(normal range: 25-100);
– serum vitamin B12: 1163 pg/mL (normal range
200-900);
– serum erythropoietin (EPO): < 0.5 mU/mL on
two separate determinations (normal range: 10-
18);
– circulating erythrocyte mass: 48 mL/kg (normal
value for men: ≤ 36).
Now the clinical scenario is markedly changed. The bone
marrow morphology is diagnostic for a chronic myeloprolif-
erative disorder, and the other  ancillary tests, besides
excluding pseudoerythrocytosis, are in line with this inter-
pretation. Considering the differential diagnosis of  chronic
myeloproliferative disorders, chronic myelogenous leukemia
(CML) is obviously ruled out.3 The diagnosis of essential
thrombocythemia has as a prerequisite the presence of a
sustained thrombocytosis, not less than 6003109/L.4 The
two major diagnostic options in the present case are idio-
pathic myelofibrosis (IM) and PV. Both frequently exhibit a
slight thrombocytosis, the main differential feature being an
increase in the red blood cell mass in the latter. However,
IM has a typical peripheral blood picture with dacryocytes,
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Figure 1. 
a: patient's chest X-ray (frontal view) shows bilateral
fibrothorax, pulmonary emphysema, congestion of the pul-
monary vasculature and a right-sided pleural effusion;
b: bone marrow biopsy at diagnosis shows trilineage
hyperplasia, more pronounced in the megakaryocyte lin-
eage, with medium degree atypia (hematoxylin-eosin,
original magnification 1003). 
erythroblasts and frequently immature granulocytes, and
the bone marrow usually shows collagen fibrosis instead of a
mere increase of reticulin fibers.5 It should be noted that a
normal LAP score, as our patient had, is strong evidence
against the diagnosis of CML, but not of PV, being observ-
able in a minority of patients.6
A diagnosis of polycythemia vera with cardiac
and respiratory insufficiency was made, and the
patient was discharged with a program of ambula-
tory follow-up. Chemotherapy with hydroxyurea
was scheduled in the probable evenience that addi-
tional phlebotomies would be insufficient to con-
trol the disease. The patient neglected medical care. 
He showed up again about a year and a half
afterward, complaining of marked anorexia, astenia
and weight loss. Physical evaluation showed
increased splenomegaly, while his cardiorespiratory
condition was stable. Hemocytometry showed pan-
cytopenia: Hb 8 g/dL; WBC 1,5003106/L with a
normal differential, platelets 1123109/L. Bone mar-
row biopsy showed a conspicuous reduction of the
cellularity together with a marked increase in fibro-
sis (Figure 2b). The patient was lost to follow-up
again and died in another hospital a few weeks
afterwards of overwhelming pneumonia.
Bone marrow insufficiency caused by progressive reticulin
fibrosis is the most frequent final step in the natural history
of PV.7
A few adjunctive distinctive features in a rather linear
clinical presentation, i.e. a patient affected by acute bron-
copulmonary infection complicating COPD, induced us to
look for and demonstrate the coexistence of a chronic myelo-
proliferative disorder and COPD. Among the chronic
myeloproliferative disorders, PV seemed to represent the
best diagnostic option. Nevertheless, we had to confront a
major obstacle. In 1975 the Polycythemia Vera Study
Group (PVSG) proposed a set of simple diagnostic criteria
for PV, whose main objective was to avoid the inclusion in
study protocols of patients with SP.1 According to the PVSG
guidelines, PV can be diagnosed in a patient when an
increase in the red cell mass and a normal arterial oxygen
saturation are present, together with splenomegaly or two of
the following minor criteria: thrombocytosis, leukocytosis,
markedly elevated leukocyte  alkaline phosphatase, increas-
ed serum vitamin B12. The role of serum vitamin B12 con-
centration as a minor diagnostic criterium for PV has been
recently questioned.8 The PVSG criteria have been widely
accepted in the scientific community , with more than 270
citations in the Science Citation Index9 and adopted almost
universally also in clinical practice. In particular, according
to these criteria, no polycythemic patient whose arterial oxy-
gen saturation is less than 92% can be considered to have
PV. The present patient had two major (an increased red
cell mass and splenomegaly) and  one minor diagnostic crite-
ria  (thrombocytosis), but had a low arterial oxygen satura-
tion due to chronic respiratory insufficency.
A few years ago, in his comments on the differential diag-
nosis of polycythemia, Ernest Beutler stated that “It is not
the red cell mass that is helpful in leading one to
the diagnosis of secondary polycythemia but rather
the absence of leukocytosis, thrombocytosis and
splenomegaly”.10 We believe that in this case PV is not
merely the best diagnosis among the  chronic myeloprolifer-
ative syndromes, but is undoubtedly distinguished from SP
by the undetectable levels of serum EPO found in our
patient. Serum EPO was not included in the original PVSG
criteria, presumably because of the overlap between
patients and controls in the lower range of the values, due
to methodological problems. With more accurate laborato-
ry techniques, serum EPO has been recently demonstrated
to be a very sensitive marker, capable of accurately discrimi-
nating between PV and SP.11-13 Due to the high prevalence
of COPD the coexistence of PV and SP in the same patient
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Figure 2.
a: bone marrow biopsy at diagnosis shows an increase in
reticulin fibers, particularly evident around megakaryo-
cytes (Gomori's silver impregnation, original magnifica-
tion 2503).
b: bone marrow biopsy after 18 months shows extensive
collagenization and a marked decrease of cellularity
(hematoxylin-eosin, original magnification 1003).
186 Polycythemia vera in COPD
is not an improbable event;2 such patients could be missed
to diagnosis if the stringent PVSG criteria are acritically
adopted. Did our patient really have SP with superimposed
PV, or did he simply have misdiagnosed PV? About fifteen
years had passed between the first discovery of polycythemia
and the patient's hospitalization, and this interval is similar
to the median duration of survival in large groups of PV
patients.14,15
In conclusion, we would like to propose that, although the
occurrence of PV in COPD is potentially rare, care should
be taken to single out these patients in order to offer them
proper care and counselling. Serum EPO determination
might help in the initial identification of PV in COPD
patients in whom suspicion is justified by laboratory and
clinical findings.
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